The GRITPHARMA has signed a comprehensive strategic cooperation agreement with JUVENTAS Therapeutics of the United States of up to 200 million RMB. Obtain exclusive rights to develop the genetic drug of JUVENTAS Therapeutics in China, and Opened a new journey for the company's gene therapy drug development.
GP-51801 encodes stromal cell-derived factor 1 (SDF-1), the preclinical studies have shown that SDF-1 promotes tissue repair by activating natural stem cell repair pathways, promoting new blood vessel formation and preventing persistent cell death.The project has been approved by the US FDA to enter Phase II clinical trials.
Dr. Douglas Losordo, Ph.D., principal investigator of the trial and director of the Fenberg Cardiovascular Institute at the Northwestern University's Feinberg School of Medicine, said severe limb ischemia is a devastating disease and there are no FDA-approved treatments. New regenerative therapies have the potential to restore blood flow and improve the clinical outcomes of these patients.
Gene therapy can provide a higher clinical benefit to CLI patients than traditional drugs and surgical treatment. SDF-1 is a potent chemotactic agent for hematopoietic stem cells (HSCs), and most terminal organs retain the SDF-1 repair pathway, including the heart, peripheral blood vessels, kidneys, skin, liver, and eyes. Developed to treat the CLI, the patient population is huge and will further boost the field of human gene therapy that is currently slowly recovering. he development of this project marks the beginning of the GRITPHARMA’s involvement in the bio-pharmaceutical field and is a milestone on the road to becoming a biomedical leader in the era of innovation!